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Epidermolysis bullosa (EB) is a clinically and geneti-
cally heterogeneous group of blistering disorders
with considerable morbidity and mortality. Two
decades ago, EB entered the molecular era with the
identification of mutations in specific genes ex-
pressed within the cutaneous basement membrane
zone; mutations in 14 genes have now been identified.
This progress has now formed the basis for develop-
ment of novel molecular therapies for this disease.
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INTRODUCTION
New knowledge about the mutations that cause epidermo-
lysis bullosa (EB) has had a major impact on its diagnosis and
management (Table 1). First, identification of a mutation has
been used to confirm EB diagnosis and to allow precise classi-
fication of patients in subcategories of EB. This knowledge
has also been helpful in deciphering the mode of inheritance
in instances where the family constellation did not readily
lend itself to a definitive determination of autosomal dominant
versus autosomal recessive inheritance. Finally, the identifica-
tion of mutated genes and specific mutations has led to DNA-
based prenatal testing and preimplantation genetic diagnosis
in families at risk for recurrence of EB. In spite of this
impressive progress, there is no specific or effective treatment
for this group of currently intractable diseases.
EB 2009—THE STATE OF THE ART IN EB RESEARCH
EB 2009, recently held in Vienna, was organized by the EB
patient support organization, DEBRA, with the following
goals: (1) to review progress in and barriers to fundamental EB
research, and the development of clinical solutions; (2) to
consider research aspects of EB not addressed to date; (3) to
identify unexplored opportunities and relevant research from
complementary areas; and (4) to arrive at a community
consensus on research and development priorities.
Attendance was by invitation and was limited to senior EB
researchers and clinicians, with 20 invited speakers and 50
discussants. In addition, two DEBRA task forces convened
separate meetings to address issues relating to research on the
aggressive squamous cell carcinomas (SCCs) that develop
primarily in patients with recessive dystrophic EB (RDEB),
and the use of animal models as a tool for basic research and
on preclinical testing of treatments for EB.
DEVELOPMENT OF MOLECULAR THERAPIES FOR EB
Recent excitement in EB research relates, in part, to the
development of several approaches to address directly the
molecular defects that lead to skin fragility, which manifests
clinically as blisters and erosions. Complementary technol-
ogies, mostly in the advanced stages of preclinical research or
already in early-stage clinical trials, have been reported
(Table 2) (Tamai et al., 2009; Uitto, 2009).
Gene therapy
The first attempts to treat patients with EB by molecular
approaches used an ex vivo strategy to correct the
consequences of a genetic mutation for junctional EB (JEB)
by introducing wild-type complementary DNA into the
patient’s own skin-derived stem cells, which were then
grown into epithelial sheets for grafting (Mavilio et al., 2006).
Specifically, keratinocytes from the patient, with an identified
mutation in the LAMB3 gene encoding one of the three
subunit polypeptides of laminin 332, were cultured and
transduced with the expression vector in cell culture.
Corrected cell populations with stem cell characteristics
were then expanded clonally and grown into epithelial sheets
that were transplanted back to the patient’s skin in an area
specifically prepared by laser ablation of the existing
epidermis. At a 5-year follow-up, the graft revealed sustained
phenotypic reversal of the blistering, and the persistent skin
graft continued to express laminin 332 protein. This proof of
principle for an ex-vivo gene therapy has encouraged the
development of similar technologies to address the defective
or absent COL7A1 gene that results in RDEB. Concerns
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over the risks associated with the use of retroviral vectors in
gene therapy for other indications (notably development
of leukemia in patients who have undergone treatment
for severe combined immunodeficiency disease) have,
particularly in Europe, led to a more stringent regulatory
environment. Thus, technologies are being modified to
address the theoretical risk of carcinogenesis due to the
random integration of the transgene into the human genome.
Several presentations at the conference focused on the
development of ‘‘safer’’ vectors for EB gene therapy, either
by targeting specific sites in the genome by self-inactivating
viral vectors or through delivery mediated by transposons or
zinc-finger nucleases. Alternative technologies such as
spliceosome-mediated RNA trans-splicing have also shown
promise in preclinical studies.
Protein replacement therapy
An alternative to gene delivery may be protein therapy,
whereby purified wild-type protein is administered to the skin
by topical application or local injection. In animal models,
some success has been achieved by systemic delivery
through intravenous injection. The feasibility of recombinant
protein therapy has been suggested by recent observations
that injection of human type VII collagen into collagen VII-
deficient ‘‘knock-out’’ mice can reverse the blistering
phenotype (Remington et al., 2009). Specifically, the
untreated Col7a1/ mice, which recapitulate the clinical,
genetic, histopathological, and ultrastructural features of
recessively inherited dystrophic forms of EB, usually die
within the first week of life due to extreme fragility of the skin
and mucous membranes (Heinonen et al., 1999). Intradermal
injections of recombinant type VII collagen extended the life
span of these mice, and some survived as long as 20–25
weeks. Immunofluorescence analysis of the treated mice,
which were initially completely devoid of type VII collagen,
revealed that the injected collagen homed to the cutaneous
basement membrane zone, eliciting repair, with formation of
anchoring fibrils and resulting in reduced blistering (Remington
et al., 2009). Based on these and other observations, clinical
trials for phase I/II studies will commence, once the necessary
quantities of GMP-purified human type VII collagen are secured
and regulatory authority approval is obtained.
Protein replacement is attractive because no viruses or
living cells are involved in its delivery. In addition,
dermatologists are familiar with the intracutaneous injection
of extracellular matrix components, including collagen-
containing preparations. Although similar pre-clinical studies
use the delivery of laminin 332 for patients with JEB, the
Table 1. Clinical and genetic heterogeneity of epidermolysis bullosa1
EB variant Inheritance Location of blisters Mutated genes Altered or missing proteins
Simplex
EBS AD (AR) Basal layer of the epidermis KRT5, KRT14, PLEC1 Basal keratins
EB-MD AR Basal layer of the epidermis PLEC1 Plectin
Junctional
JEB-H, JEB-nH AR LL LAMA3, LAMB3, LAMC2, COL17A1 Laminin 332, type XVII collagen
EB-PA AR Basal layer–LL interface ITGA6, ITGB4, PLEC1 a6b4 Integrin, plectin
Dystrophic
DDEB, RDEB AD, AR Sub-lamina densa COL7A1 Type VII collagen
Other2
Lethal Acantholytic AR Suprabasal layers of the epidermis DSP Desmoplakin
Kindler syndrome AR Mixed KIND1/FERMT1 Kindlin1
Ectodermal dysplasia/
skin fragility syndrome
AR Suprabasal layer of the epidermis PKP1 Plakophilin1
EBS, other3 AR Basal keratinocytes with lack of
hemidesmosomal inner plaque
DST BPAG1 (epithelial isoform)
Abbreviations: AD, autosomal dominant; AR, autosomal recessive; EB-MD, epidermolysis bullosa with muscular dystrophy; EB-PA, epidermolysis bullosa
with pyloric atresia; EDS, ectodermal dysplasia syndrome; JEB-H, JEB Herlitz; JEB-nH, JEB non-Herlitz variant; LL, lamina lucida; RDEB and DDEB, recessive
and dominant dystrophic forms of EB.
1This classification highlights the most common subtypes of EB, i.e., simplex (EBS), junctional (JEB), and dystrophic (DEB), which are differentiated by the
location of blister formation within the cutaneous basement membrane zone, as determined by ultrastructural analysis and/or immuno-epitope mapping.
2Rare, phenotypes with superficial or mixed locations of blistering have been proposed to belong to the spectrum of EB phenotypes (Fine et al., 2008).
3A single patient with skin blistering, together with late-onset neurological abnormalities, has been described (Groves et al., 2010). Assessment of the
genotype/phenotype correlation is, however, complicated by the presence of CADASIL (cerebral arteriopathy, autosomal dominant, with subcortical infarcts
and leukoencephalopathy) due to a separately inherited heterozygous mutation in NOTCH3.
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success of this approach with any particular protein will
depend on the nature of the protein and the rate of its
turnover in skin. The half-lives of these molecules in human
skin have not yet been determined, but recent studies in mice
have suggested that type VII collagen has a long half-life,
owing to the newly synthesized protein being relatively stable
and persistent (Fritsch et al., 2009).
Cell-based therapies
Cell-based therapeutic approaches (focused primarily on two
cell types) have been tested recently in patients with EB. First,
direct injection of either autologous or allogeneic fibroblasts
intradermally around the area of blistering has been tested in
patients with reduced or absent expression of type VII
collagen (Wong et al., 2008). As expected, the autologous
fibroblasts did not cause major adverse effects, and the
allogeneic fibroblasts elicited only a minor inflammatory
reaction. Interestingly, the injected cells did not appear to
persist in the skin beyond a few weeks; yet, the benefits, in
terms of reduced blistering tendency and improved wound
healing, were sustained for several months. In addition,
patients who lacked type VII collagen expression completely
seemed to benefit little from the intradermal fibroblast
injection, whereas those showing significant, yet reduced,
baseline expression of COL7A1 showed definite improve-
ment. The mechanism for improvement in the latter patients
was suggested to be, at least in part, sustained cytokine-
mediated upregulation of the expression of the mutant type
VII collagen gene product in the resident cells (both
fibroblasts and keratinocytes) of patients who showed
residual levels of synthetic activity from their mutant allele.
These patients, therefore, synthesize mutant type VII col-
lagen, which is partially functional and forms functional
anchoring fibrils. It appears, therefore, that injection of
cultured fibroblasts from unrelated donors might be useful
in a select subgroup of patients with RDEB.
Cell-based therapies for RDEB have been extended more
recently to the use of stem cells for RDEB. These clinical trials
were predicated upon preclinical animal studies that used
a type VII collagen ‘‘knock-out’’ mouse model as a target for
bone marrow-derived cell transfer (Chino et al., 2008; Tolar
et al., 2009). In these studies, green fluorescent protein (GFP)-
expressing mice were used as donors of bone marrow cells,
enabling the investigators to trace donor cells in the
recipients. In one study, a specific subpopulation of bone
marrow-derived cells, positive for the signaling lympho-
cytic activation molecule family receptor (CD150þ /CD48),
extended the survival of some animals when transferred to
Col7a1/ mice, which usually die within the first week of
life (Tolar et al., 2009). The surviving animals showed
evidence of engraftment of GFP-positive donor cells in the
skin, production of type VII collagen, and healing of skin
blisters. Another study showed successful engraftment of
GFP-positive bone marrow cells in the skin after embryonic
bone marrow cell transfer, and the recipient mice showed
significantly reduced blistering after birth and an extended
survival of up to several weeks (Chino et al., 2008).
Examination of the recipient mice showed evidence of
differentiation of bone marrow-derived cells toward fibro-
blastic phenotypes and expression of type VII collagen. In the
latter studies, intriguingly, mice subjected to embryonic bone
marrow cell transfer became tolerant to GFP, and subsequent
grafting of GFP-expressing skin did not induce the production
of antibodies against GFP (Chino et al., 2008). Collectively,
these studies attest to the possibility that stem cells can be a
source of dermal cells, such as fibroblasts, for regeneration of
damaged skin in heritable skin diseases, such as EB.
The first allogeneic bone marrow cell transfer trial on
patients with RDEB was initiated in 2007, and at the time of
this Conference (September, 2009), five individuals had been
transplanted (Wagner et al., 2009). Histopathological exam-
ination suggested chimerism with donor-derived cells in the
skin varying from 11 to 38%, the donor cells being largely
perivascular. These cells also showed a tendency to migrate
to the cutaneous basement membrane zone, with ultrastruc-
tural evidence of synthesis of anchoring fibrils. On an
optimistic note, these early observations suggest that bone-
marrow cell transfer could provide a means to correct the
Table 2. Examples of molecular therapies under development for different forms of epidermolysis bullosa
Target disease Approach Research stage/clinical trial
JEB
RDEB
Grafting of genetically modified epidermal keratinocytes Pilot study (Mavilio et al., 2006)
Planned for clinical trial 2010
RDEB Localized injection of allogeneic fibroblasts into the skin Pilot study (Wong et al., 2008); phase II 2010
RDEB Application of chimeric skin equivalents (fibroblasts from healthy
donors and patient keratinocytes)
Phase IIb ongoing
RDEB Allogeneic bone marrow transplantation (standard procedures) Phase I/II (Wagner et al., 2009)
RDEB Bone marrow transplantation with reduced intensity conditioning Phase I/II (Christiano et al., 2009)
RDEB Protein replacement by intradermal injection (type VII collagen) Phase I (Remington et al., 2009)
EBS
DDEB
Silencing of the dominant mutant allele by siRNA Preclinical development
JEB Grafting of autologous keratinocytes from patients with revertant mosaicism Pilot study (Gostynski et al., 2009)
Abbreviations: DDEB, dominant forms of dystrophic epidermolysis bullosa; EBS, epidermolysis bullosa simplex; JEB, junctional epidermolysis bullosa;
RDEB, recessive forms of epidermolysis bullosa; siRNA, small interfering RNA.
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basement membrane defect in patients with RDEB. While
these trials were being conducted in a multi-disciplinary
environment consisting of pediatric oncologists, dermatolo-
gists, gastroenterologists, anesthesiologists, and other specia-
lists, together with nursing staff specializing in the care of
bone marrow transplant patients, two out of the five patients
entered in the study had died from complications of the
conditioning for bone marrow transfer or of consequences of
immunological mismatch. With this perspective, new trials in
different academic institutions have been initiated with a
reduced-intensity conditioning regimen (Christiano et al.,
2009). The rationale for the reduced-intensity conditioning is
that, instead of complete myeloablation of the recipient’s
own immune system, the patient initially becomes chimeric,
with subsequent and gradual replacement of the immune
system (Satwani et al., 2008). This approach is expected to
have lower morbidity, and even mortality, as it may avoid the
susceptibility to infection and cytokine storm associated with
the aggressive conditioning regimen. It was pointed out,
however, that even the milder conditioning does not avoid
the complications related to mismatch of the graft with the
recipient’s immune system, which may lead to graft-versus-
host disease. It should be emphasized that these studies are at
the early stages of development and a full refinement in
experimental settings in specialized centers is required before
these modalities can be recommended for EB patient
populations in general. The critical questions relating to
bone marrow-derived cell transfer pertain to the specific
identity of the cells, the mechanisms by which they home
from bone marrow to the circulation and eventually to areas
in need of repair, their ultimate differentiated phenotype,
location, and persistence, as well as the roles they have in
improved skin structural integrity.
PREVENTION AND TREATMENT OF COMPLICATIONS
IN EB
Compromised wound healing and tissue fibrosis
The major consequences of recurrent blistering of the skin in
patients with EB are the development of erosions and ulcers
with compromised wound healing, while patients with
certain subtypes of EB, especially the dystrophic variants,
show extensive scarring that can lead to mutilation,
particularly of the hands and feet (Fine and Mellerio, 2009a).
Although the primary molecular pathology underlying
blister formation in the major forms of EB has been
characterized with the delineation of mutations in 14 genes
encoding skin structural proteins, it is the downstream
consequences of these mutations that have the greatest
impact on disease morbidity and mortality (Fine et al., 2008).
For example, although skin fragility in dystrophic EB is
caused by disruption of the anchoring fibril protein, type VII
collagen (Chung and Uitto, 2010), the major disease burden
results from ‘‘frustrated’’ attempts at tissue repair, in which
the normal processes of granulation tissue formation, re-
epithelialization, and extracellular matrix remodeling are
compromised; this leads to delayed wound healing, chronic
inflammation, fibrosis, scarring, and an increased risk of
developing SCCs (Fine and Mellerio, 2009b). Understanding
the precise biology and pathology of the abnormal tissue
environment is clearly germane to developing new strategies
to counter these downstream events and effectively manage
patients. This topic was addressed in detail.
It is evident that the investigators have not yet established
a full understanding of the dystrophic or junctional EB
‘‘wound expression profiles’’, data that are seemingly
fundamental for developing rational therapies (Wessagowit
et al., 2004). Surprisingly perhaps, to date there have been
only limited numbers of studies (or, in some instances, no
data) on measurements of oxidative stress, pro-inflammatory
cytokines, growth factors, T-cell subsets, toll-like receptor
function, epithelial/mesenchymal signaling pathways, or
fibroblast/myofibroblast biology in EB tissue (Tyring et al.,
1989; Chopra et al., 1992). Indeed, despite recent data
implicating certain T-cell-associated cytokines as contribu-
tors to the chronic inflammation that is linked to malignancy
(Langowski et al., 2006; Wang et al., 2009), this topic has not
yet been explored in the setting of EB. With regard to pro-
inflammatory cytokines, for example, the last few years have
seen the introduction of a number of recombinant proteins
that target specific cytokines or their receptors, e.g. IL-1,
tumor necrosis factor-a, and T-cell-associated cytokines such
as IL-17 and IL-23 (Fitch et al., 2007; Mo¨ssner et al., 2008;
Neven et al., 2008; Zhu et al., 2009), but we do not yet know
whether these or related types of therapy might have clinical
relevance to individuals living with EB. Transforming growth
factor-b has been implicated as important for the excessive
fibrosis found in non-EB diseases (Sargent et al., 2010) and in
mouse models, but it is not known whether countering the
effects of this cytokine, for example, by using neutralizing
antibodies to transforming growth factor-b1 or by increasing
the expression of the anti-scarring alternative isoform
transforming growth factor-b3, might reduce scarring and
contractures in patients with EB (Young et al., 2009). Nor has
a scientific rationale been defined for possible trials of
recombinant growth factors such as platelet-derived growth
factor, basic fibroblast growth factor, or granulocyte macro-
phage colony-stimulating factor in EB (Barrientos et al.,
2008). One innovation, the use of topical inhibitors of NF-kB,
such as ethyl pyruvate, was thought to have therapeutic
potential, notwithstanding that NF-kB signaling has not been
fully evaluated in EB skin.
It is likely that many of the aberrant cellular processes in
wound healing that lead to delayed tissue repair and fibrosis
overlap with cancer-associated inflammation in EB, and that
an improved understanding of the skin ‘‘ecosystem’’, for
example, in terms of chemokines, growth factors, and
remodeling enzymes, is pivotal in driving translational
research on this disorder.
SCC in EB
One of the devastating consequences of recurrent blistering,
particularly in RDEB, is the development of SCCs (Mallipeddi
et al., 2004a, b; Fine et al., 2009). These tumors occur in the
vast majority of patients with RDEB in their third or fourth
decade, primarily on the hands and feet. In contrast to SCCs
in the general population, RDEB-associated malignancies are
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aggressive, with a high propensity for metastatic spread.
Few therapeutic options exist, except for surgical removal
(often necessitating amputation of the affected limbs, with
uncertain effects on the overall survival). In addition to their
relentless malignant behavior, these tumors appear to be multi-
focal and multiclonal, as suggested by observations of several
primary tumors coexisting in the same patient (Tomita et al.,
2003). Furthermore, distinguishing malignant foci in chroni-
cally disrupted epidermis is a significant diagnostic challenge.
Taken together, these grim characteristics call for a
concerted effort to improve the diagnosis, staging, and
treatment of these tumors. In recognition of the significance
of this problem, a task force was established 3 years ago by
DEBRA to develop new diagnostic and therapeutic ap-
proaches to skin cancer in EB. Systematic investigations into
the pathomechanisms that distinguish RDEB-associated SCC
from other SCCs have yet to be carried out. Such studies
would be of value in identifying potential biomarkers for this
malignancy; these are sorely needed due to the difficulties
associated with the clinical diagnosis of RDEB-associated
SCC. In addition, such studies may lead to previously
unreported therapeutic targets. At present, it is unknown
whether RDEB-SCC represents a distinct neoplastic entity
with a unique assortment of pathway activations, leading to
its clinically aggressive behavior, or whether it is indis-
tinguishable from rare aggressive SCCs in patients without
RDEB. Several groups have recently performed compara-
tively small-scale microarray cell and tissue analyses to
address this question (Arbiser et al., 2004; Mallipeddi et al.,
2004b; Kivisaari et al., 2008), but progress has been
hampered by the apparent lack of sufficient material for
molecular analysis. Although DEBRA has supported the early-
stage development of an EB SCC Bank (http://www.netzwerk-eb.
de/e439/e480/inhalt539/RequestformSCCTissuebank_ger.pdf?
preview=preview), hosting tissue samples and a limited number
of derived cell lines, it is necessary to supplement these
resources by collecting clinical samples to make the most of
the limited material available in laboratories around the world. It
should be noted that SCC samples from EB patients are usually of
poor quality, with high microbial loads; understandably, a
surgeon’s priority is the patient, not the sample. A major obstacle
is stable funding to maintain and administer centralized tissue
banks for this purpose.
It seems likely that the continuous tissue reorganization
associated with chronic inflammatory processes distinguishes
RDEB-SCC from sporadic SCC. But why are these tumors so
aggressive? Comparing the molecular footprints of RDEB-SCC
with those of related tumors in non-RDEB patients from the
skin and oral mucosa (head and neck SCCs), for which ample
datasets have already been assembled (Dong et al., 2001;
Chung et al., 2004), represents one useful approach to this
question. Others address how molecular events related to
continuous tissue remodeling support the malignant traits of
keratinocytes, including the investigation of proteolytically
generated fragments of extracellular matrix components, such
as laminin 332 and perlecan, as well as the expression and
function of integrin subunits upregulated in skin cancer,
inflammation, and regeneration. Largely, these studies are in
the preclinical phases and address the molecular mechanisms
shared by malignant and regenerating tissues.
Treating RDEB-associated SCC by surgical means is
primarily palliative. Although targeted agents currently being
tested in sporadic SCC (e.g. EGFR inhibitors) were considered
for RDEB-associated SCC, these interventions are not likely to
be curative due to the aggressive nature of RDEB-associated
SCCs. In addition, their multifocal nature—consistent with
distinct molecular events and pathways driving different
tumors in the same patient—and their putative genetic
instability could contribute to treatment resistance. A
different approach would be ‘chemopreventive’: using
topically formulated antiinflammatory drugs to reduce the
tumor initiation and progression driven by continuous
chronic inflammation and excessive regenerative processes.
However, the negative consequences of this approach,
related to undue interference with wound healing and the
difficulty of defining suitable end points and time frames in
which to evaluate the efficacy of specific regimens, must be
considered. Instead, it may be worthwhile to use the existing
animal models for preclinical testing of these types of
approaches.
THE ROLE OF PATIENT ADVOCACY ORGANIZATIONS—
THE PARADIGM OF DEBRA INTERNATIONAL
Increasingly, patient advocacy organizations are becoming
partners in the research process, not only providing research
funding and access to patients, but also helping to identify
research priorities, lobbying governments for funding and
equitable access to healthcare, and promoting industrial
collaboration (Terry et al., 2007). Nowhere is this more
important than in orphan disease fields, where patients,
clinicians, and investigators face the challenges of a rare but
disabling and life-limiting condition, largely neglected by
‘‘big pharma’’ because of niche market size.
DEBRA International is the primary charitable patient-support
organization working on behalf of patients with EB and their
families. It is a network of approximately 30 autonomous
national DEBRA organizations, working together on areas of
mutual interest, including lobbying nationally and interna-
tionally for political and funding recognition, support for
research, and provision of support services, including social
welfare, information on EB, and, in some countries, a
specialist EB nursing service. DEBRA International has, as
its mission, ‘‘working for a life free of pain’’; this mission
embraces not only research into the causes and possible
treatments for EB, but also delivery of care. At the same time,
DEBRA manages the expectations of patients who hear too
often the promises of ‘major research breakthroughs’, for
whom only a cure represents exactly that, while giving those
patients a public voice. The activities of patient advocacy
organizations, such as DEBRA International, are critical for
our progress.
EB 2009—SUMMARY AND CONCLUSIONS
EB 2009 was highly successful in assessing the current state of
EB research and in advancing the agenda. This meeting
reflected the progress made in research, particularly in
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molecular therapies, toward treatment, and perhaps cure of
EB. The areas of active investigation include gene therapy,
protein replacement approaches, and cell-based (particularly
stem-cell and fibroblast) therapies, and some of these
approaches are already entering the clinical arena. It is clear,
however, that these approaches are at the early stages of
investigation, and there are a number of uncertainties, even
controversies, surrounding them. For example, are the gene
therapy approaches, which currently concentrate on the
development of safer and more efficient vectors for the
delivery of genes to the skin, so as to avoid the potential of
tumorigenesis due to random integration of the DNA into the
recipient genome, the ‘‘holy grail’’ for EB treatment? Are they
going to be successful in eliciting permanent correction of the
primary gene defect? Is the protein replacement approach,
which is likely to elicit a transient effect, a primary treatment
modality requiring multiple treatments or could it serve as a
complementary approach to other modalities, such as gene
therapy, which might provide a permanent cure? The bone
marrow transplantation approach, which has been reported
to be preliminarily successful in some individuals, has also
resulted in considerable morbidity and even mortality
associated with the aggressive recipient conditioning of the
traditional bone marrow transfer protocols. New clinical
trials adopting modified, perhaps less aggressive, condition-
ing approaches are being initiated. Are these approaches
effective in reversing the blistering phenotype, and what are
the overall risk/benefit ratios? Yet further approaches, which
are yet to be reported, combine a better understanding of
both EB and advanced technologies—notably variations of
stem-cell technologies (including induced pluripotent stem
cells)—both as research tools and, ultimately, possible
therapies. These, to our knowledge previously unreported,
approaches bring with them still more questions and both
technical and regulatory challenges in establishing their
efficacy and safety. Collectively, it is hoped that perhaps not
in too distant future, we may have treatments, either in the
form of a combination of therapies or in a single modality
approach, to help patients suffering from EB.
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